Cambrex Corporation (NYSE:CBM) CEO Steven M. Klosk sold 12,000 shares of Cambrex Corporation stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $61.39, for a total transaction of $736,680.00. Following the sale, the chief executive officer now directly owns 95,328 shares in the company, valued at $5,852,185.92. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Shares of Cambrex Corporation (NYSE CBM) opened at 58.50 on Friday. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of 22.27 and a beta of 2.28. Cambrex Corporation has a 12-month low of $38.30 and a 12-month high of $62.95. The firm’s 50-day moving average is $58.97 and its 200-day moving average is $55.37.

Cambrex Corporation (NYSE:CBM) last announced its earnings results on Friday, August 4th. The biotechnology company reported $0.76 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.76. The business had revenue of $134.55 million for the quarter, compared to the consensus estimate of $136.82 million. Cambrex Corporation had a net margin of 17.36% and a return on equity of 24.92%. Cambrex Corporation’s quarterly revenue was up 13.4% on a year-over-year basis. During the same period last year, the firm posted $0.68 earnings per share. On average, equities analysts predict that Cambrex Corporation will post $3.02 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Cambrex Corporation (NYSE:CBM) CEO Sells $736,680.00 in Stock” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/05/cambrex-corporation-nysecbm-ceo-sells-736680-00-in-stock.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Flinton Capital Management LLC boosted its position in shares of Cambrex Corporation by 3.8% in the first quarter. Flinton Capital Management LLC now owns 1,870 shares of the biotechnology company’s stock worth $103,000 after buying an additional 68 shares during the last quarter. Creative Planning boosted its position in shares of Cambrex Corporation by 162.6% in the second quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock worth $105,000 after buying an additional 1,093 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Cambrex Corporation by 9.3% in the second quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock worth $105,000 after buying an additional 150 shares during the last quarter. YorkBridge Wealth Partners LLC boosted its position in shares of Cambrex Corporation by 20.2% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,874 shares of the biotechnology company’s stock worth $106,000 after buying an additional 315 shares during the last quarter. Finally, Meeder Asset Management Inc. acquired a new position in shares of Cambrex Corporation during the first quarter worth approximately $109,000. Institutional investors and hedge funds own 98.28% of the company’s stock.

CBM has been the topic of several research reports. Zacks Investment Research raised shares of Cambrex Corporation from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a report on Thursday, May 11th. BidaskClub raised shares of Cambrex Corporation from a “hold” rating to a “buy” rating in a report on Friday. Finally, ValuEngine lowered shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $64.00.

Cambrex Corporation Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Insider Buying and Selling by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.